Skip to main content
SRTOY logo

Sartorius Stedim Biotech S.A. (SRTOY) Stock Price & Analysis

Sartorius Stedim Biotech S.A. (SRTOY) — price $24.44 (-1.37%), as of the Nov 19, 2026 trading session; market cap $23.8B.

Educational signal · not a buy or sell recommendation · How to read this

$24.44 −$0.34 (-1.37%) Market Cap $23.8B

Sartorius Stedim Biotech S.A. · SRTOY · Healthcare · Medical - Instruments & Supplies

Sartorius Stedim Biotech S.A. operates globally, providing essential instruments and consumables to the biopharmaceutical industry. Their product range is extensive, featuring items such as cell lines, cell culture growth media, and bioreactors.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • WST · West Pharmaceutical Services, Inc. · 92 /100
  • RMD · ResMed Inc. · 95 /100
  • ALC · Alcon Inc. · 80 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$24.44
Change on the day-1.37%
52-week range$17.25–$26.54
Market capitalisation$23.8B—
Price / earnings (trailing)67.13
Shares traded on the day1.6K
Beta (volatility vs the S&P 500)1.14

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $18, high $26, latest $24. $26 $18 high $26 Oct 17, 2025 Nov 19, 2026 · $24 $24Oct 17, 2025$25Oct 31, 2025$25Nov 14, 2025$24Nov 28, 2025$25Dec 12, 2025$24Dec 26, 2025$26Jan 9, 2026$24Jan 23, 2026$22Feb 6, 2026$22Feb 20, 2026$19Mar 6, 2026$19Mar 20, 2026$20Apr 2, 2026$23Apr 17, 2026$18May 1, 2026$18May 15, 2026$21May 29, 2026$20Jun 12, 2026$20Jun 26, 2026$21Jul 10, 2026$19Jul 24, 2026$20Aug 7, 2026$23Aug 21, 2026$22Sep 4, 2026$23Sep 18, 2026$24Oct 2, 2026$24Oct 16, 2026$25Oct 30, 2026$25Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Sartorius Stedim Biotech (SRTOY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Favorable read

Read on: Sep 24, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Neutral
Revenue Growth Weak
Debt/Equity Weak
ROE Neutral
Gross Margin Moderate

Read on: May 2, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On May 2, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Sartorius Stedim Biotech (SRTOY), and what does it report?

Short answer

Sartorius Stedim Biotech S.A. operates globally, providing essential instruments and consumables to the biopharmaceutical industry. Their product range is extensive, featuring items such as cell lines, cell culture growth media, and bioreactors. Healthcare / Medical Instruments & Supplies Headquarters: Zone Industrielle Les Paluds, Aubagne, PAC, 13781, FR. It employs 10,265 people and is led by Rene Faber. In Q3 FY2026 it reported revenue of €758M and net income of €95M. The market values it at $23.8B.

2 · Latest results

What do the latest results show for Sartorius Stedim Biotech (SRTOY)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of €758M.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026€758M€95M€0.01 (diluted)
Q2 FY2026€778M€95M€0.01 (diluted)
Q1 FY2026€774M€90M€0.01 (diluted)
Q4 FY2025€765M€37M€0.0048 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Sartorius Stedim Biotech (SRTOY)?

Short answer · as of

The distress and quality screens read Altman Z 36.64 · Piotroski F 7. Trailing ratios: ROE 7.7% · ROA 4.0% · current ratio 1.22 · earnings yield 1.5% · free-cash-flow yield 1.2%.

5 · Score methodology

How is Sartorius Stedim Biotech scored?

Research dated 2026-09-12.

Compared with a conventional laboratory-instrument vendor, Sartorius Stedim participates in much more of the customer’s production chain. Its portfolio connects cell lines and media with bioreactors, separation, purification, fluid management, secure storage and workflow analytics.

That breadth ties demand to biopharmaceutical development and manufacturing activity rather than isolated equipment replacement. The useful comparison is therefore the balance among equipment, consumables, services and software, not healthcare-instrument valuation multiples alone.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
AstraZeneca PLC (AZNCF) Named competitor$189.90 Sep 25, 2026$294B— Model unavailable
EssilorLuxottica S.A. (ESLOF) Named competitor$195.80 Nov 19, 2026$89.8B— Model unavailable
Fresenius SE & Co. KGaA (FSNUY) Named competitor$14.29 Nov 19, 2026$32.2B— Model unavailable
Novo Nordisk A/S (NONOF) Named competitor$39.50 Nov 19, 2026$174B— Model unavailable
West Pharmaceutical Services, Inc. (WST) Same industry, near in market value$404.02 Nov 18, 2026$28.1B— 5-pillar · not comparable
ResMed Inc. (RMD) Same industry, near in market value$242.61 Nov 18, 2026$34.1B— 5-pillar · not comparable
Alcon Inc. (ALC) Same industry, near in market value$74.52 Nov 19, 2026$35.8B— 5-pillar · not comparable
Baxter International Inc. (BAX) Same industry, near in market value$25.39 Nov 19, 2026$13.1B— 5-pillar · not comparable
The Cooper Companies, Inc. (COO) Same industry, near in market value$60.33 Nov 19, 2026$11.5B— 5-pillar · not comparable
Medline Inc. Class A Common Stock (MDLN) Same industry, near in market value$37.84 Nov 19, 2026$49.8B— 5-pillar · not comparable
Repligen Corporation (RGEN) Same industry, near in market value$170.29 Nov 19, 2026$10.9B— 5-pillar · not comparable
Avantor, Inc. (AVTR) Same industry, near in market value$15.37 Nov 18, 2026$10.4B— 5-pillar · not comparable

The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held SRTOY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported SRTOY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Sartorius Stedim Biotech (SRTOY)?

Read these with our analysis →

Sartorius Stedim Biotech Healthcare Stock: Key Questions Answered

The last question is answered from this page's own dated data, not from the research.

What makes Sartorius Stedim more than a medical-instruments supplier?

Its products span the bioprocess itself, from cell cultivation and fermentation through filtration, purification, storage and transport. Services and analytics software extend that role beyond selling laboratory hardware.

Why do cell and gene therapy kits matter to Sartorius Stedim?

Presterilized kits and hollow-fiber membrane devices place Sartorius Stedim inside specialized cell and gene therapy processes. They broaden the portfolio from core bioreactors into fluid handling, separation and material transfer.

What is the SRTOY stock price today?

The last price recorded for Sartorius Stedim Biotech S.A. (SRTOY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 18 figures on this page — 15 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • 5. How is Sartorius Stedim Biotech scored?: Sector / industry (provider taxonomy); Business description; Trailing twelve-month ratio set
  • FAQ: What makes Sartorius Stedim more than a medical-instruments supplier?: Sector / industry (provider taxonomy); Business description
  • FAQ: Why do cell and gene therapy kits matter to Sartorius Stedim?: Business description
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.